

## Rutgers Cancer Institute of New Jersey



# Clinical Trials Connection

*A Cancer Resource for Healthcare Professionals*

Winter 2017

### [Resources for Physicians](#)

 [Send to a Colleague](#)

 [Join Our Mailing List](#)



**Janice M. Mehnert, MD**

is the director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School. As a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, Dr. Mehnert provides comprehensive care to those with skin cancer and soft tissue malignancies and is instrumental in the development of clinical trial protocols testing novel therapies.

Contact Dr. Mehnert:  
[mehnerja@cinj.rutgers.edu](mailto:mehnerja@cinj.rutgers.edu)  
917-991-4174

## Phase I Clinical Trials

[View printable version](#)

### NCI/CTEP #9681: A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors

The study aims to:

- Determine the dose limiting toxicity (DLT) and recommended Phase II dose (RP2D) of the combination of cabozantinib and nivolumab and separately the combination of cabozantinib, nivolumab and ipilimumab in patients with solid tumors.

[Learn more about this trial](#)

### NCI/CTEP #9782: A Phase I Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors

The study aims to:

- Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BMN 673 seven day schedule in combination with carboplatin and paclitaxel.
- Determine the maximum tolerated dose (MTD) and

## Clinical Trial Spotlight

### Precision Medicine Clinical Trials

Rutgers Cancer Institute is offering a variety of clinical trials that focus on genomic analysis and precision medicine efforts, including treatment for rare and poor prognosis cancers and more common malignancies.

[Learn more about these trials](#)

### Other Available Trials

[Breast](#)

[Gastrointestinal/  
Hepatobiliary](#)

[Gynecologic](#)

[Hematologic Oncology](#)

[Melanoma](#)

[Pediatric](#)

[Phase I](#)

[Prostate](#)

[Thoracic](#)



A Cancer Center Designated by the  
National Cancer Institute

recommended phase 2 dose (RP2D) of BMN 673 three day schedule in combination with carboplatin and paclitaxel.

- Observe and record anti-tumor activity of BMN 673 in combination with carboplatin and paclitaxel.

[Learn more about this trial](#)

---

## NCI/CTEP 9825: A Phase II Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

The study aims to:

- Evaluate the association of BROCA-HR with the clinical activity of cediranib/olaparib, as measured by progression-free survival (PFS), in women with recurrent platinum-sensitive ovarian cancer.
- Assess the clinical activity of cediranib/olaparib, as measured by objective response, in women with recurrent platinum-resistant ovarian cancer.

[Learn more about this trial](#)

---

## CC-486-CAGEN-001: A Phase I, Open- Label, Multicenter, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

The study aims to:

- Evaluate the bioequivalence of CC-486 (Oral Azacitidine) when administered once daily as one 300mg tablet relative to two 150mg tablets during the pharmacokinetics phase of the study in adult cancer subjects.
- Evaluate the safety and tolerability of CC-486 (Oral Azacitidine) during the pharmacokinetics phase and Vidaza (Azacitidine for Injection) during the extension phase of the study in adult cancer subjects.

[Learn more about this trial](#)

---

## MK3475-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (Vulvar Cohort Only)

The study aims to:

- Evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarker-unselected subjects with any one of multiple types of advanced (metastatic and/or unresectable) solid tumors.

[Learn more about this trial](#)



As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.

[Learn more](#)

Cancer Institute of New Jersey, Rutgers, The State University of New Jersey,  
195 Little Albany St., New Brunswick, NJ 08903